Bang yj et al. lancet 2010 376: 687-697
웹Bang YJ, et al. Lancet 2010;376:687–697. 胃癌和胃食管交界癌的HER2 检测推荐流程 患者肿瘤样本 IHC 0 1+ 2+ ISH 3+ – + 需要进行曲妥珠单抗治疗 《胃癌HER2检测指南》编写组 … 웹2024년 6월 23일 · Lancet. 2010; 376: 687-697. Summary; Full Text; Full Text PDF; PubMed; Scopus (5240) ... Bang YJ ; et al. Pembrolizumab versus paclitaxel for previously treated, …
Bang yj et al. lancet 2010 376: 687-697
Did you know?
웹2010년 8월 19일 · Lancet (London, England), 19 Aug 2010, 376(9742): 687-697 DOI: 10.1016/s0140-6736(10)61121-x PMID: 20728210 A comment on this article appears in " … 웹2010년 8월 28일 · The Lancet. Volume 376, Issue 9742, 28 August–3 September 2010, Pages 687-697. Articles. Trastuzumab in combination with chemotherapy versus …
웹2012년 1월 28일 · X Paoletti, K Oba, T Burzykowski, et al., the GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research International Collaboration) ... YJ Bang, E … 웹Lancet. 2010;376(9742):687–97. CrossRefPubMed Bang YJ et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–97. CrossRef PubMed
웹2010년 9월 18일 · Volume 376 Number 9745 p929-1024. Current Issue; Online First; Close. Download full issue. ... Dong-bo Ou; Full-Text HTML; PDF p957. p957. ... Lancet and … 웹Lancet 376:687–697 CrossRefPubMed Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
웹2010년 8월 28일 · Background: Trastuzumab, a monoclonal antibody against human epidermal growth factor receptor 2 (HER2; also known as ERBB2), was investigated in …
웹2010년 8월 20일 · et al. Global cancer facts and figures 2007. ... Bang Y-J, Van Cutsem E, Feyereislova A, et al, ... (ToGA): a phase 3, open-label, randomised controlled trial. Lancet … chitin padding웹Treatment Delivery. All enrolled patients received at least one cycle of apatinib. The median number of treatment cycles was 3.62 (range 1.04–25.46) and the number of average treatment cycles was 5.98 (range 1.04–25.46). Twenty-seven patients (56.3%) started the treatment with an initial dose of 500 mg, and nine of them experienced dose reduction from 500 mg to 250 … grasmere holiday rentals웹2024년 8월 13일 · Bang YJ, Van Cutsem E, Feyereislova A et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial [published correction appears in Lancet. 2010 Oct … chitinous setae웹2024년 2월 16일 · Gastric cancer is not a top-10 malignancy in the United States but represents one of the most common causes of cancer death worldwide. Biological differences between tumors from Eastern and Western countries add to the complexity of identifying standard-of-care therapy based on international trials. grasmere hotel salisbury wiltshire웹2016년 5월 3일 · Bang YJ ; Van Cutsem E ; Feyereislova A ; et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376: 687-697. chitinous teeth웹Gastric cancer is the fourth most common cancer globally, and is the second most common cause of death from cancer worldwide. About three-quarters of newly diagnosed cases in 2008 were from Asian countries. With a high mortality-to-incidence ratio, management of gastric cancer is challenging. We discuss evidence for optimum management of gastric cancer in … chitinous teeth crayfish웹2024년 9월 16일 · 1 Bang YJ, et al., Lancet. 2010; 376 (9742): 687-697.. 2 Janjigian YY, et al., J Clin Oncol. 2024; 39 (suppl 15): 4013. grasmere idaho plane crash